Business, energy, technology, markets and global industry news from Business News Today

TETON-2

PharmaDeviceNews TETON-2
Pharma & Biotech

FDA accepts United Therapeutics’ Tyvaso application for idiopathic pulmonary fibrosis

The FDA has accepted United Therapeutics’ supplemental Tyvaso application for idiopathic pulmonary fibrosis after combined TETON data showed a 111.8 mL advantage in forced vital capacity over placebo at 52 weeks.

Read More
Pharma & Biotech

Can Tyvaso change the treatment pathway for idiopathic pulmonary fibrosis after TETON-1?

IPF has few durable treatment options. Tyvaso’s TETON data may test whether inhaled therapy can reset the regulatory and commercial playbook.

Read More
Tyvaso TETON-2 data marks first inhaled therapy to slow IPF fibrosis in phase 3 trial
Pharma & Biotech

United Therapeutics targets 2026 FDA submission for Tyvaso IPF indication after TETON-2 success

TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.

Read More